First Trust Advisors LP raised its stake in Glaukos Corporation (NYSE:GKOS) by 57.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,964 shares of the medical instruments supplier’s stock after purchasing an additional 16,354 shares during the period. First Trust Advisors LP owned 0.13% of Glaukos Corporation worth $1,865,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of GKOS. Teachers Advisors LLC grew its stake in Glaukos Corporation by 5.7% in the fourth quarter. Teachers Advisors LLC now owns 27,789 shares of the medical instruments supplier’s stock valued at $953,000 after purchasing an additional 1,506 shares during the last quarter. Nationwide Fund Advisors grew its stake in shares of Glaukos Corporation by 749.3% during the first quarter. Nationwide Fund Advisors now owns 89,101 shares of the medical instruments supplier’s stock worth $4,571,000 after acquiring an additional 78,610 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in shares of Glaukos Corporation during the first quarter worth about $102,000. American Century Companies Inc. grew its stake in shares of Glaukos Corporation by 2.6% during the first quarter. American Century Companies Inc. now owns 135,082 shares of the medical instruments supplier’s stock worth $6,930,000 after acquiring an additional 3,458 shares during the last quarter. Finally, Comerica Bank purchased a new stake in shares of Glaukos Corporation during the first quarter worth about $1,562,000.

In other news, Director Orbimed Advisors Llc sold 325,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $37.93, for a total value of $12,327,250.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas William Burns sold 1,212 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $41.25, for a total value of $49,995.00. The disclosure for this sale can be found here. Insiders sold a total of 980,200 shares of company stock worth $37,900,263 over the last quarter. Company insiders own 16.40% of the company’s stock.

Glaukos Corporation (NYSE GKOS) opened at 40.75 on Wednesday. Glaukos Corporation has a 52 week low of $28.72 and a 52 week high of $52.49. The firm’s market capitalization is $1.40 billion. The stock’s 50 day moving average price is $42.03 and its 200 day moving average price is $45.46.

WARNING: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/13/first-trust-advisors-lp-has-1-87-million-holdings-in-glaukos-corporation-gkos.html.

GKOS has been the subject of a number of research reports. Zacks Investment Research downgraded Glaukos Corporation from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 12th. BidaskClub raised Glaukos Corporation from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Piper Jaffray Companies reissued a “buy” rating and issued a $56.00 price target on shares of Glaukos Corporation in a report on Thursday, August 3rd. Finally, Roth Capital decreased their price target on Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $52.33.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Stock Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related stocks with our FREE daily email newsletter.